Literature DB >> 9331097

Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.

F Salazar-Onfray1, T Nakazawa, V Chhajlani, M Petersson, K Kärre, G Masucci, E Celis, A Sette, S Southwood, E Appella, R Kiessling.   

Abstract

Human melanoma-specific HLA-A2 restricted CTLs have recently been shown to recognize antigens expressed by melanoma lines and normal melanocytes, including Melan-A/Mart-1, gp100, gp75, and tyrosinase. Herein, we define HLA-A2-restricted CTL epitopes from a recently cloned melanocortin 1 receptor (MC1R), which belongs to a new subfamily of the G-protein-coupled receptors expressed on melanomas and melanocytes. Thirty-one MC1R-derived peptides were selected on the basis of HLA-A2-specific motifs and tested for their HLA-A2 binding capacity. Of a group of 12 high or intermediate HLA-A2 binding peptides, three nonamers, MC1R244 (TILLGIFFL), MC1R283 (FLALIICNA), and MC1R291 (AIIDPLIYA), were found to induce peptide-specific CTLs from peripheral blood mononuclear cells of healthy HLA-A2+ donors after repeated in vitro stimulation with peptide-pulsed antigen-presenting cells. The CTLs raised against these three HLA-A2+-restricted peptides could recognize naturally processed peptides from HLA-A2+ melanomas and from Cos7 cells cotransfected with MC1R and HLA-A2. CTLs induced by the MC1R291 peptide (but not induced or induced only to a very low extent by the other two MCR1 peptide epitopes) showed cross-reactions with two other members of the melanocortin receptor family, which are more broadly expressed on other tissues. Taken together, our findings have implications in relation both to autoimmunity and immunotherapy of malignant melanomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331097

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo.

Authors:  Masahiro Hayashi; Ying Jin; Daniel Yorgov; Stephanie A Santorico; James Hagman; Tracey M Ferrara; Kenneth L Jones; Giulio Cavalli; Charles A Dinarello; Richard A Spritz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

2.  Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.

Authors:  A Escobar; M López; A Serrano; M Ramirez; C Pérez; A Aguirre; R González; J Alfaro; M Larrondo; M Fodor; C Ferrada; F Salazar-Onfray
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 3.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

4.  Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP).

Authors:  Jamileh Hashemi; Claire Worrall; Daiana Vasilcanu; Mårten Fryknäs; Luqman Sulaiman; Mohsen Karimi; Wen-Hui Weng; Weng-Onn Lui; Christina Rudduck; Magnus Axelson; Helena Jernberg-Wiklund; Leonard Girnita; Olle Larsson; Catharina Larsson
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

5.  Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells.

Authors:  Padraig D'Arcy; Wessen Maruwge; Barry Wolahan; Limin Ma; Bertha Brodin
Journal:  PLoS One       Date:  2014-04-30       Impact factor: 3.240

6.  Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.

Authors:  C Worrall; N Suleymanova; C Crudden; I Trocoli Drakensjö; E Candrea; D Nedelcu; S-I Takahashi; L Girnita; A Girnita
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

7.  Induction of cytotoxic T lymphocytes from peripheral blood of human histocompatibility antigen (HLA)-A31(+) gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma.

Authors:  Y Nabeta; H Sahara; K Suzuki; H Kondo; M Nagata; Y Hirohashi; Y Sato; Y Wada; T Sato; T Wada; T Yamashita; K Kikuchi; N Sato
Journal:  Jpn J Cancer Res       Date:  2000-06

8.  Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation.

Authors:  Naida Suleymanova; Caitrin Crudden; Claire Worrall; Anica Dricu; Ada Girnita; Leonard Girnita
Journal:  Oncotarget       Date:  2017-07-17

Review 9.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

10.  Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker.

Authors:  F Salazar-Onfray; M López; A Lundqvist; A Aguirre; A Escobar; A Serrano; C Korenblit; M Petersson; V Chhajlani; O Larsson; R Kiessling
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.